Achieve life sciences reports second quarter 2025 financial results; provides updates on cytisinicline program

Seattle and vancouver, british columbia, aug. 07, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for second quarter 2025. “this quarter represents a significant step forward for achieve.
ACHV Ratings Summary
ACHV Quant Ranking